Integrated Analysis of Assays Drive Early Developability Assessment of Antibodies

February 24, 2025

Biotherapeutics are now a leading class of therapy, but their development comes with unique challenges. Crucial to their success later in the clinic is their developability, their key biophysical and biochemical properties that make a candidate suitable. In the case of antibodies, these include, among others, thermal stability, aggregation propensity, and expression efficiency. Some developability properties can be predicted by in silico methods, but many others must be empirically tested using a battery of standardized bioassays. These developability assay panels are now being run on hundreds of antibody candidates in parallel at an early stage in development, to avoid costly failure of drug candidates later. This scale of testing poses new analysis challenges, including processing of high throughput data and fast candidate profiling using results from the complete panel. In this poster, we demonstrate how Genedata Screener enables large-scale early assessment of developability through automation of data analysis and integrated data management.